# Differential Role of CD318 in Tumor Immunity Affecting Prognosis in Colorectal Cancer Compared to Other Adenocarcinomas

## TL;DR

This study shows that CD318 has different effects on the immune system in colorectal cancer compared to other cancers, influencing patient outcomes.

## Contribution

The paper reveals a novel differential role of CD318 in tumor immunity across cancer types, particularly in colorectal cancer.

## Key findings

- High CD318 expression is common in COAD, CESC, LUAD, and PAAD.
- CD318 in CESC, LUAD, and PAAD promotes immunosuppression via TGFβ1 upregulation.
- In COAD, CD318 enhances cytotoxic immune responses through CD8+ T cells and NK cells.

## Abstract

Background/Objectives: CD318 (also known as CDCP1) is a transmembrane protein that is overexpressed in many cancers and contributes to tumor progression, invasion, and metastasis by activating SRC family kinases through phosphorylation. Emerging evidence also suggests that CD318 plays a role in modulating the tumor immune microenvironment, although its precise mechanism in tumor progression is still not well understood. Methods: To investigate this, we analyzed the expression and immune-related functions of CD318 using the publicly available data from The Cancer Genome Atlas (TCGA) across colorectal adenocarcinoma (COAD), cervical squamous cell carcinoma (CESC), lung adenocarcinoma (LUAD), and pancreatic adenocarcinoma (PAAD). Results: All four cancers exhibited a high level of CD318 expression. Notably, in CESC, LUAD, and PAAD, plasmin-mediated cleavage of CD318 leads to phosphorylation of SRC and protein kinase C delta (PKCδ), which activates HIF1α and/or p38 MAPK. These downstream effectors translocate to the nucleus and promote the transcriptional upregulation of TGFβ1, fostering an immunosuppressive tumor microenvironment through Treg cell recruitment. In contrast, this signaling cascade appears to be absent in COAD. Instead, our analysis indicate that intact CD318 in COAD interacts with the surface receptors CD96 and CD160, which are found on CD8+ T cells and NK cells. Conclusions: This interaction enhances cytotoxic immune responses in COAD by promoting CD8+ T cell and NK cell activity, offering a possible explanation for the favorable prognosis associated with high CD318 expression in COAD, compared to the poorer outcomes observed in CESC, LUAD, and PAAD.